NewAmsterdam Pharma
NewAmsterdam Pharma is dedicated to advancing treatments for cardiovascular disease (CVD) and lipid-related conditions. The company focuses on innovative therapies to help people with unmet medical needs, aiming to reduce the global impact of CVD, which is the leading cause of death worldwide. With a strong leadership team of experts in lipidology and cardiovascular research, NewAmsterdam Pharma is developing novel therapies, including CETP inhibitors like obicetrapib, to lower LDL cholesterol and improve patient outcomes. The company is actively engaged in clinical trials, research, and collaborations to bring new solutions to patients and address the persistent gaps in lipid-lowering treatments.
Industries
Nr. of Employees
small (1-50)
NewAmsterdam Pharma
NewAmsterdam Pharma, 20803 Biscayne Blvd, Suite #105, Aventura, FL 33180
Products
Investigational CETP inhibitor (oral small molecule)
An investigational, highly selective oral small-molecule CETP inhibitor under clinical development to lower LDL-C as an adjunct to maximally tolerated lipid-lowering therapy.
Investigational fixed-dose oral combination (CETP inhibitor + NPC1L1 inhibitor)
Fixed-dose oral combination of a CETP inhibitor with an intestinal cholesterol absorption inhibitor being developed to enhance LDL-C lowering compared with monotherapy.
Investigational CETP inhibitor (oral small molecule)
An investigational, highly selective oral small-molecule CETP inhibitor under clinical development to lower LDL-C as an adjunct to maximally tolerated lipid-lowering therapy.
Investigational fixed-dose oral combination (CETP inhibitor + NPC1L1 inhibitor)
Fixed-dose oral combination of a CETP inhibitor with an intestinal cholesterol absorption inhibitor being developed to enhance LDL-C lowering compared with monotherapy.
Services
Provision of scientific information and medical science liaison engagement for healthcare professionals; requestable via medical information channels.
Assessment and management of requests for compassionate or expanded access to investigational treatments according to internal criteria and regulatory requirements.
Two-year research grant program for early-career investigators supporting basic, translational, clinical and outcomes research in lipid biology and related fields.
Provision of scientific information and medical science liaison engagement for healthcare professionals; requestable via medical information channels.
Assessment and management of requests for compassionate or expanded access to investigational treatments according to internal criteria and regulatory requirements.
Two-year research grant program for early-career investigators supporting basic, translational, clinical and outcomes research in lipid biology and related fields.
Expertise Areas
- Clinical trial management
- Cardiovascular drug development
- Lipid biology and CETP-targeted therapeutics
- Biomarker and translational research
Key Technologies
- CETP inhibition (small-molecule mechanism)
- Oral small-molecule fixed-dose combination therapy
- Coronary computed tomography angiography (CCTA) quantitative imaging
- Lipid and neurodegenerative biomarker assays (LDL-C, ApoB, Lp(a), CSF sterols, Aβ42/40)
News & Updates
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
In June 2025, the company announced positive topline data from their BROADWAY trial, indicating promising results in Alzheimer’s disease research.
The company scheduled an R&D day to discuss recent scientific advancements and clinical progress.
The company will present at investor conferences to share progress and future plans.
A scientific publication detailing how obicetrapib affects LDL cholesterol levels.
Research article on the safety profile and efficacy data of obicetrapib.
Study results showing the impact of obicetrapib combined with statins on LDL levels.
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
In June 2025, the company announced positive topline data from their BROADWAY trial, indicating promising results in Alzheimer’s disease research.
The company scheduled an R&D day to discuss recent scientific advancements and clinical progress.
The company will present at investor conferences to share progress and future plans.
A scientific publication detailing how obicetrapib affects LDL cholesterol levels.
Research article on the safety profile and efficacy data of obicetrapib.
Study results showing the impact of obicetrapib combined with statins on LDL levels.